VERS completes antibacterial Phase II enrollment

Biosearch (NMerc:BIO) partner Versicor (VERS) completed enrollment in an open-label Phase II trial of BIO's Dalbavancin antibiotic in 60 hospitalized patients with Gram-positive skin and soft tissue i...